Trinity Biotech (TRIB)

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

Company profile

Ticker

TRIB

Exchange

NASDAQ

Website

www.trinitybiotech.com

CEO

Ronan O'Caoimh

Incorporated

Ireland

Location

Ireland

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Ortho Clinical Diagnostics • Idexx Laboratories • Myriad Genetics • Lantheus • Neogen • QuidelOrtho • Meridian Bioscience • Celldex Therapeutics • Achieve Life Sciences • Oxford Immunotec Global ...

SEC CIK

0000888721

Corporate docs

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

TRIB stock data

1M 1Y 5Y

Calendar

25 May 22

2 Jul 22

31 Dec 22

Financial summary

Financial statements Chart TRIB financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q1 2022

TRIB institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Orasure

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Abon, Acon, add, advent, Aesku, Affinion, aggressively, albeit, Allere, altogether, anniversary, Architec, bad, Bejing, BioLine, Biosensor, catching, chair, Chairperson, Chembio, consecutive, contrast, covenant, customary, Dan, DCA, deploying, destabilised, devote, digit, discourage, disgorgement, doubtful, drawdown, drawn, easing, endeavor, envisaged, euroimmun, exceptionally, extinguished, fear, flex, founder, Goldsand, Guaranty, harmonized, headcount, inbound, incarceration, inova, Jeon, junior, Kekedjian, keyboard, Kim, Korean, laundering, lessening, LIBOR, mandatorily, MHRA, Michael, MiCo, monthly, NaN, normalisation, normalised, nurse, outbound, paper, PATRIOT, persisted, prioritising, published, puttable, ramped, regain, Russia, SD, Sebia, shift, Soo, Sung, TinaQuant, trailing, twelve, unchanged, uncured, unrestricted, unusually, VTM, VWAP, Wanta, widespread, Wondf

Removed: AB, Abram, accelerated, Accutrend, advanced, Alto, AMPLICOR, Ampliscreen, analyzed, apportioned, Athena, Atlanta, AxSYM, Barco, Beckman, BEP, Biosite, Burger, Cardiolipin, cautionary, Centaur, choice, coagulation, concentrate, Conformit, Coulter, creating, debarment, Diego, dissolution, dominant, enabling, enrollment, Enzygnost, ETIMAX, freedom, Geographically, Georgia, gold, IFRIC, IMI, Immulite, IMx, indenture, Inv, Konelab, labeling, Legionella, lent, Liasion, liquid, Lorrelle, modifying, netted, notional, Ortho, OTC, Palo, Pineview, Qualitative, Quant, quantitative, remunerated, repealing, replacing, San, Sharon, stable, Tina, Triag, unigold, unparalleled, vast, virtue, Wampole, xiii

From filing 20-F 2021 FY

Financial reports

View all

20-F/A

2021 FY

Annual report (foreign) (amended)

25 May 22

20-F

2021 FY

Annual report (foreign)

2 May 22

20-F